Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01918371 · ClinicalTrials.gov registry record
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 323
- Enrollment target
NCT01918371 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 323 participants.
The verdict
NCT01918371 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 323 participants
- Enrollment target
Study Summary
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
Interventions
- DRUG Anti-VEGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2013-08-02 |
| Est. Completion | 2014-09-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01918371
The ClinicalTrials.gov registry entry for NCT01918371 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-VEGF is the first listed.
NCT01918371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01918371 about?
NCT01918371 is a clinical study titled "A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema". This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
What is the current status of trial NCT01918371?
This trial is currently completed. The enrollment target is 323 participants. The study started on 2013-08-02. Estimated completion is 2014-09-04.
What interventions are being tested in trial NCT01918371?
The interventions under investigation include: Anti-VEGF (DRUG).
Who is sponsoring clinical trial NCT01918371?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.